Two phase 2 trials, BIRCH and POPLAR, showed a benefit in OS for patients who received single-agent atezolizumab with NSCLC with high PD-L1 expression (assessed by the SP142 PD-L1 immunohistochemical assay) across multiple lines of therapy [34]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.